title: Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.
abstract: OBJECTIVE
  The aim of this study was to assess prospectively the effectiveness and safety of a new version of the dedicated bifurcation BiOSS stent, the sirolimus-eluting BiOSS LIM, for the treatment of distal left main (LM) stenosis.
  
  
  RESULTS
  This was a prospective international registry which enrolled patients with NSTE-ACS or stable angina. Provisional T-stenting was the mandated strategy. The primary endpoint was the cumulative rate of cardiac death, myocardial infarction (MI) and target lesion revascularisation (TLR) at 12 months. Twelve-month quantitative coronary angiography endpoints included late lumen loss and percent diameter stenosis. A total of 74 patients with distal LM stenosis were enrolled. Seventy-three of the 74 patients (aged 67±9 years, 23% women, 20.3% NSTE-ACS, SYNTAX score 22.4±4.4) were successfully treated with the BiOSS LIM stent, with additional side branch placement of regular DES in 11 patients (14.9%). Periprocedural MI occurred in one (1.4%) patient. The 12-month MACE rate was 9.5% without cardiac death or definite stent thrombosis. TLR and MI rates were 6.8% (n=5) and 2.7% (n=2), respectively.
  
  
  CONCLUSIONS
  The use of the BiOSS LIM dedicated bifurcation stent for the treatment of distal LM stenosis was feasible and safe, with promising long-term clinical effectiveness.
authors.affiliation: Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Gil
authors.forename: Jacek
authors.initials: J
authors.lastname: Bil
authors.forename: Maik J
authors.initials: MJ
authors.lastname: Grundeken
authors.forename: Luis A
authors.initials: LA
authors.lastname: Iñigo Garcia
authors.forename: Dobrin
authors.initials: D
authors.lastname: Vassilev
authors.forename: Adam
authors.initials: A
authors.lastname: Kern
authors.forename: Tomasz
authors.initials: T
authors.lastname: Pawłowski
authors.forename: Joanna J
authors.initials: JJ
authors.lastname: Wykrzykowska
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D003251:Constriction, Pathologic / Q000188:drug therapy*; D017023:Coronary Angiography / Q000379:methods; D023903:Coronary Restenosis / Q000628:therapy; D023921:Coronary Stenosis / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D017239:Paclitaxel / Q000627:therapeutic use; D011446:Prospective Studies; D012042:Registries; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013995:Time; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D020123:Sirolimus